在不间断的达比加特兰和阿皮克萨班之间对血管损伤的凝血反应的差异:一项临床前性随机研究
Yasuhiro Ikami1, Daisuke Izumi1, Shinya Fujiki1
1Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Heart rhythm
|July 17, 2024
概括
不间断的达比加特兰是一种直接的血栓抑制剂,不像阿皮克萨班,在血管损伤期间不会阻止血栓生成. 这项研究阐明了口服抗凝剂对凝血反应的直接作用.
科学领域:
- 心血管医学 心血管医学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 连续直接口服抗凝剂 (DOAC) 在血管损伤期间对凝血的影响尚不清楚.
- 了解这些反应对于管理正在接受手术的抗凝治疗患者至关重要.
研究的目的:
- 为了比较患者接受不间断的直接血栓激素抑制剂与直接XA因子抑制剂的血管损伤的凝血反应.
- 调查大比加特兰和阿皮克萨班对血栓生成和凝血因子的差异性影响.
主要方法:
- 一项前性随机研究分配了经过导管切除的心房患者接受达比加特兰或阿皮克萨班.
- 血液样本在三个时间点收集:手术前,血管穿刺前和血管穿刺后.
- 测量了凝血标志物,包括1+2蛋白质凝血片段,以评估凝血反应.
主要成果:
- 与阿皮克萨班组相比,达比加特兰组在血管穿刺后的血红蛋白片段1+2水平,即血红蛋白生成的标志物,显著更高.
- 在达比加特兰接受者的血管穿刺后,抗血素水平下降.
- 在血管穿刺后,阿皮克萨班接受者的蛋白C和抗血素水平都下降了.
结论:
- 不间断的达比加特兰治疗不会抑制对血管损伤的反应中的血栓生成.
- 相比之下,不间断的阿皮克萨班似乎调节了对血管损伤的凝血反应.
- 这些发现突出了在手术血管事件期间不同DOAC的不同作用机制.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
668
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
668
Introduction to Hemostasis
7.1K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
7.1K
Coagulation
6.0K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.0K
Extrinsic and Intrinsic Pathways of Hemostasis
7.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.0K
Formation of the Platelet Plug
5.7K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
5.7K


